



Citation for published version:

Campbell, JP, Heaney, JLJ, Shemar, M, Baldwin, D, Griffin, AE, Oldridge, E, Goodall, M, Afzal, Z, Plant, T, Cobbold, M, Jefferis, R, Jacobs, JFM, Hand, C & Drayson, MT 2017, 'Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum and immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool', *Clinical Chemistry and Laboratory Medicine*, vol. 55, no. 3, pp. 424-434. <https://doi.org/10.1515/cclm-2016-0194>

DOI:

[10.1515/cclm-2016-0194](https://doi.org/10.1515/cclm-2016-0194)

Publication date:

2017

Document Version

Peer reviewed version

[Link to publication](#)



University of Bath

General rights


Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



Supplementary Figure 1. Assessment of interference from common interference agents in the measurement of κ FLC (top) and λ FLC (bottom) by Seralite[®]. Change (mg/L) as a result of interference (x-axes) was assessed by adding interference agents (y-axes) to serum containing normal κ (12.72 mg/L) and λ (10.88 mg/L) FLC levels. The concentration of interference agents is the final concentration in the sample.



Supplementary Figure 2. Lot-to-lot variation from three independent lots of Seralite[®] for κ (left) and λ (right) when measuring 65 samples containing varying levels of free light chains.

Supplementary Table 1. Precision data using samples with varying concentrations of free light chains For intra- and inter-day precision samples with the following concentrations were used: normal (15.9 mg/L κ FLC, 13.4 mg/L λ FLC), elevated (51.8 mg/L κ FLC, 40.5 mg/L λ FLC) and highly-elevated (136.6 mg/L κ FLC, 136.7 mg/L λ FLC). For intra-reader precision samples with the following concentrations were used: normal (11.7 mg/L κ FLC, 8.8 mg/L λ FLC), elevated (42.1 mg/L κ FLC, 48.6 mg/L λ FLC) and highly-elevated (156.7 mg/L κ FLC, 147.6 mg/L λ FL

CV %	Intra-day	Inter-day	Intra-reader
K FLC			
Normal	8.1	5.7	5.5
Elevated	8.1	3.6	3.1
Highly-elevated	9.6	3.9	4.5
λ FLC			
Normal	8.5	5.1	4.8
Elevated	7.4	4.6	2.0
Highly-elevated	9.0	7.1	2.6

Supplementary Table 2. Stability of FLC concentrations measured using Seralite for samples with varying concentrations of FLCs: low, normal, elevated and high. Data shown is the median change in FLC concentration from baseline (mg/L) across three different testing conditions: ambient room temperature (21–24°C), refrigeration (3–5 °C) and freeze-thawing. Samples stored at room temperature were tested at 0, 1, 8, 24, 48 and 72h. Samples stored in the fridge were tested at 0, 1, 2, 3, 4 and 7 days. To test the effects of freeze thaw cycles, samples were tested on day 0 then frozen and re-tested daily over 6 consecutive days.

	Low		Normal		Elevated		High	
	K 4.5 mg/L	λ 6.7 mg/L	K 13.5 mg/L	λ 10.9 mg/L	K 38.8 mg/L	λ 40.4 mg/L	K 124.8 mg/L	λ 122.0 mg/L
Ambient room temperature 21–24°C: 0–72h	0.7	1.4	-2.1	-0.4	-3.1	-0.2	-7.8	-7.8
3–5°C: 0–7 days	0.7	1.3	-0.1	-0.3	0.4	1.3	2.3	1.6
Freeze thaw 6 cycles	0.8	0.4	1.1	1.4	-0.5	2.9	3.3	4.7

Supplementary Table 3. Samples from multiple myeloma patients previously shown to give erroneously low results by Freelite® due to antigen excess were analysed using Seralite®. Grey boxes highlight where antigen excess resulted in incorrect diagnosis using the standard dilution on Freelite®: patient 1 changes from a lambda to kappa diagnosis with re-dilution; patient 5 initially demonstrated a ratio within the normal diagnostic range (0.26–1.65) but then indicated a monoclonal lambda FLC with re-dilution. Seralite® was able to correctly identify all monoclonal FLCs in these patients using the ratio obtain from the standard dilution.

Sample and involved FLC	Freelite® (RocheHitachiCobas®C501) Standard dilution (κ 1 in 5, λ 1 in 8)			Freelite® (RocheHitachiCobas®C501) Offline dilution (1 in 100)			Seralite® dual K and λ lateral flow device Standard dilution (1 in 3)			Seralite® Offline dilution (1 in 20/1 in 400)		
	K	λ	K:λ	K	λ	K:λ	K	λ	K:λ	K	λ	K:λ
1 - κ	0.77	6.35	0.12	664		105	78.8	< 2.5	> 32			
2 - κ	37.64	8.66	4.3	31594		3648	> 200	3.4	>58	22320		6565
3 - λ	5.63	39.86	0.14		695	0.01	< 2.5	184.2	< 0.013			
4 - κ	41.47	24.27	1.7	454		19	54.5	11.7	4.7			
5 - λ	6.51	15.63	0.42		1772	0.01	< 2.5	> 200	< 0.01		39480	>0.0006
6 - κ	22.09	10.77	2.05	5435		505	> 200	6.7	> 30	4960		740
7 - κ	51.05	8.58	5.95	562		66	> 200	< 2.5	> 80	530		>212
8 - κ	31.31	5.00	6.26	3652		3652	135.5	< 2.5	> 54			
9 - κ	44.35	6.31	7.02	6640		1052	57.2	< 2.5	> 23			
10 - κ	46.85	9.48	4.94	1611		170	59	13.7	4.3			